Oura’s healthcare ambitions take shape

Today, healthcare isn’t what’s driving Oura’s business — technically. The revenue Oura receives from contracts with health plans and providers is “de minimis” right now,

J&J adds first new indication for Caplyta since takeover

Johnson & Johnson has clinched an FDA approval for Caplyta in depression, satisfying a major driver for its $14.6bn takeover of ICT this year.

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844